On September 9, 2017, Rani Therapeutics, LLC closed the transaction. The company has received $38,663,952 in funding from 12 investors pursuant to Regulation D. The company has raised $100 million in funding so far in the transaction. The transaction included participation from Novartis AG (SWX:NOVN) and AstraZeneca PLC (LSE:AZN).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.07 USD | +16.86% | +30.93% | +112.95% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
10,946 GBX | +0.29% | -1.07% | 211B | ||
117.9 CNY | +1.66% | -0.11% | 6.44B | ||
85.53 CHF | +1.19% | -0.66% | 203B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+112.95% | 158M | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- RANI Stock
- News Rani Therapeutics Holdings, Inc.
- Rani Therapeutics, LLC announced that it has received $38.663952 million in funding from a group of investors